Meghan Mooradian, Arivarasan Karunamurthy, Hong Wang, Elizabeth Iannotti Buchbinder, Suthee Rapisuwon, Justine Vanessa Cohen, Geoffrey Thomas Gibney, Ryan J. Sullivan, Jason J. Luke, Yana G. Najjar, John M. Kirkwood, Hassane M. Zarour, Diwakar Davar. "Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): Primary analysis.." Journal of Clinical Oncology (2025). https://doi.org/10.1200/jco.2025.43.17_suppl.lba9504